Paradoxical activation of oncogenic signaling as a cancer treatment strategy.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
27 Mar 2024
Historique:
accepted: 19 03 2024
received: 21 02 2023
revised: 06 12 2023
medline: 27 3 2024
pubmed: 27 3 2024
entrez: 27 3 2024
Statut: aheadofprint

Résumé

Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress-response programs that counteract the inherent toxicity of such aberrant signaling. While inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of Protein Phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor suppressive resistance.

Identifiants

pubmed: 38533987
pii: 742013
doi: 10.1158/2159-8290.CD-23-0216
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Matheus Henrique Dias (MH)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Anoek Friskes (A)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Siying Wang (S)

Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Joao M Fernandes Neto (JM)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Frank van Gemert (F)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Soufiane Mourragui (S)

Hubrecht Institute for Developmental Biology and Stem Cell Research, Utrecht, Netherlands.

Chrysa Papagianni (C)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Hendrik J Kuiken (HJ)

Netherlands Cancer Institute, Amsterdam, Netherlands.

Sara Mainardi (S)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Daniel Alvarez-Villanueva (D)

Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.

Cor Lieftink (C)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Ben Morris (B)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Anna Dekker (A)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Emma van Dijk (E)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Lieke H S Wilms (LHS)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Marcelo S da Silva (MS)

Universidade de São Paulo, Sao Paulo, Sao Paulo, Brazil.

Robin A Jansen (RA)

Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

Antonio Mulero-Sanchez (A)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Elke Malzer (E)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

August Vidal (A)

Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.

Cristina Santos (C)

Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, L'Hospitalet de Llobregat, Spain.

Ramon Salazar (R)

Instituto Catalan de Oncología-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.

Rosangela A M Wailemann (RAM)

Instituto Butantan, São Paulo, São Paulo, Brazil.

Thompson E P Torres (TEP)

UNIFESP, Sao Paulo, Sao Paulo, Brazil.

Giulia De Conti (G)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Jonne A Raaijmakers (JA)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Petur Snaebjornsson (P)

Netherlands Cancer Institute, Amsterdam, Netherlands.

Shengxian Yuan (S)

Eastern Hepatobiliary Hospital, Shanghai, China.

Wenxin Qin (W)

Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

John S Kovach (JS)

Lixte Biotechnology Holdings, Inc., East Setauket, NY, United States.

Hugo A Armelin (HA)

Instituto Butantan, São Paulo, SP, Brazil.

Hein Te Riele (H)

Netherlands Cancer Institute, Amsterdam, N, Netherlands.

Alexander van Oudernaarden (A)

Hubrecht Institute for Developmental Biology and Stem Cell Research.

Haojie Jin (H)

State Key Laboratory of Oncogenes and Related Genes, Shanghai, China.

Roderick L Beijersbergen (RL)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Alberto Villanueva (A)

Catalan Institute of Oncology (ICO/IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Rene H Medema (RH)

University Medical Center Utrecht, Amsterdam, Netherlands.

Rene Bernards (R)

The Netherlands Cancer Institute, Amsterdam, Netherlands.

Classifications MeSH